107 related articles for article (PubMed ID: 27926949)
21. Buprenorphine produces naltrexone reversible alterations of immune status.
Carrigan KA; Saurer TB; Ijames SG; Lysle DT
Int Immunopharmacol; 2004 Mar; 4(3):419-28. PubMed ID: 15037219
[TBL] [Abstract][Full Text] [Related]
22. Buprenorphine for opioid dependence.
Milne M; Crouch BI; Caravati EM
J Pain Palliat Care Pharmacother; 2009; 23(2):153-5. PubMed ID: 19492216
[TBL] [Abstract][Full Text] [Related]
23. Reversibility of opioid receptor occupancy of buprenorphine in vivo.
Englberger W; Kögel B; Friderichs E; Strassburger W; Germann T
Eur J Pharmacol; 2006 Mar; 534(1-3):95-102. PubMed ID: 16490191
[TBL] [Abstract][Full Text] [Related]
24. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).
Pergolizzi J; Böger RH; Budd K; Dahan A; Erdine S; Hans G; Kress HG; Langford R; Likar R; Raffa RB; Sacerdote P
Pain Pract; 2008; 8(4):287-313. PubMed ID: 18503626
[TBL] [Abstract][Full Text] [Related]
25. Mixed κ/μ partial opioid agonists as potential treatments for cocaine dependence.
Bidlack JM
Adv Pharmacol; 2014; 69():387-418. PubMed ID: 24484983
[TBL] [Abstract][Full Text] [Related]
26. Safety and efficacy of buprenorphine/naloxone in opioid-dependent patients: an Italian observational study.
Magnelli F; Biondi L; Calabria R; Fiore A; Peluso E; Vonella D; Rota AG
Clin Drug Investig; 2010; 30 Suppl 1():21-6. PubMed ID: 20450242
[TBL] [Abstract][Full Text] [Related]
27. Effects of a higher-bioavailability buprenorphine/naloxone sublingual tablet versus buprenorphine/naloxone film for the treatment of opioid dependence during induction and stabilization: a multicenter, randomized trial.
Gunderson EW; Hjelmström P; Sumner M;
Clin Ther; 2015 Oct; 37(10):2244-55. PubMed ID: 26412801
[TBL] [Abstract][Full Text] [Related]
28. Highlights in opioid agonists and antagonists.
Lauretti GR
Expert Rev Neurother; 2006 Apr; 6(4):613-22. PubMed ID: 16623659
[TBL] [Abstract][Full Text] [Related]
29. Mutagenesis of the mouse delta opioid receptor converts (-)-buprenorphine from a partial agonist to an antagonist.
Bot G; Blake AD; Li S; Reisine T
J Pharmacol Exp Ther; 1998 Jan; 284(1):283-90. PubMed ID: 9435189
[TBL] [Abstract][Full Text] [Related]
30. BU48: a novel buprenorphine analog that exhibits delta-opioid-mediated convulsions but not delta-opioid-mediated antinociception in mice.
Broom DC; Guo L; Coop A; Husbands SM; Lewis JW; Woods JH; Traynor JR
J Pharmacol Exp Ther; 2000 Sep; 294(3):1195-200. PubMed ID: 10945877
[TBL] [Abstract][Full Text] [Related]
31. The diverse clinical uses of opioid receptor drugs.
Howland RH
J Psychosoc Nurs Ment Health Serv; 2010 May; 48(5):11-4. PubMed ID: 20415289
[TBL] [Abstract][Full Text] [Related]
32. Clocinnamox antagonism of the antinociceptive effects of mu opioids in squirrel monkeys.
Pitts RC; Allen RM; Walker EA; Dykstra LA
J Pharmacol Exp Ther; 1998 Jun; 285(3):1197-206. PubMed ID: 9618423
[TBL] [Abstract][Full Text] [Related]
33. Conversion from high-dose full-opioid agonists to sublingual buprenorphine reduces pain scores and improves quality of life for chronic pain patients.
Daitch D; Daitch J; Novinson D; Frey M; Mitnick C; Pergolizzi J
Pain Med; 2014 Dec; 15(12):2087-94. PubMed ID: 25220043
[TBL] [Abstract][Full Text] [Related]
34. Ultra-Low-Dose Buprenorphine for Mental Pain: Response to Ruan et al.
Yovell Y; Bar G
Am J Psychiatry; 2016 Oct; 173(10):1043-1044. PubMed ID: 27690553
[No Abstract] [Full Text] [Related]
35. [New drugs for substitution treatment of opioid dependence. Buprenorphine and 1-alpha-acetylmethadol (LAAM) ].
Petersen H; Skauge L; Svejsø J; Ege PP
Ugeskr Laeger; 2000 Nov; 162(48):6553-6. PubMed ID: 11187226
[TBL] [Abstract][Full Text] [Related]
36. Selectivity profiling of NOP, MOP, DOP and KOP receptor antagonists in the rat spinal nerve ligation model of mononeuropathic pain.
Rutten K; Schröder W; Christoph T; Koch T; Tzschentke TM
Eur J Pharmacol; 2018 May; 827():41-48. PubMed ID: 29524385
[TBL] [Abstract][Full Text] [Related]
37. [Effectiveness and tolerance of tramadol in cancer pain. A comparative study with respect to buprenorphine].
Bono AV; Cuffari S
Drugs; 1997; 53 Suppl 2():40-9. PubMed ID: 9190324
[TBL] [Abstract][Full Text] [Related]
38. Clinical update on the pharmacology, efficacy and safety of transdermal buprenorphine.
Kress HG
Eur J Pain; 2009 Mar; 13(3):219-30. PubMed ID: 18567516
[TBL] [Abstract][Full Text] [Related]
39. Conversion of chronic pain patients from full-opioid agonists to sublingual buprenorphine.
Daitch J; Frey ME; Silver D; Mitnick C; Daitch D; Pergolizzi J
Pain Physician; 2012 Jul; 15(3 Suppl):ES59-66. PubMed ID: 22786462
[TBL] [Abstract][Full Text] [Related]
40. Buprenorphine's physical dependence potential: antagonist-precipitated withdrawal in humans.
Eissenberg T; Greenwald MK; Johnson RE; Liebson IA; Bigelow GE; Stitzer ML
J Pharmacol Exp Ther; 1996 Feb; 276(2):449-59. PubMed ID: 8632309
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
